Date: Feb 22, 2012 Source: Mass High Tech
Protein Sciences recently closed a non-exclusive deal with Merck to license its insect cell line to use in Merck's vaccine research. Merck also secured an exclusive license to use Protein Sciences' expressSF+ technology for commercialization of an undisclosed vaccine candidate. Merck will pay Protein Sciences an undisclosed upfront fee. Protein Sciences' Dan Adams says the company will receive payment whenever Merck uses the technology for additional vaccine candidates. Adams also notes that other pharmaceutical companies have licensed its expressSF+ technology, including Boehringer Ingelheim. He says that more than 1,000 proteins have been developed using Protein Sciences' technology.
